Ambey Laboratories IPO
Ambey Laboratories Ltd
₹1,30,000 /2000 sharesMinimum Investment
Ambey Laboratories IPO Details
Bidding Dates | Min. Investment | Lot Size | Price Range |
---|
4 Jul ‘24 - 8 Jul ‘24 | ₹1,30,000 | 2,000 | ₹65 - ₹68 |
Ambey Laboratories is a producer of agrochemical products aimed at crop protection, with a focus on producing "2, 4-D base chemicals". The company's manufacturing processes use technologies, such as Programmable Logic Controllers (PLC) and Supervisory Control Systems.
Currently, Ambey Laboratories’ product portfolio includes 2,4-D Acid 98% TC, 2,4-D Sodium 95% SP, 2,4-D Amine in various concentrations, 2,4-D Ethyl Hexyl Ester 96% TC, 2,4-D Ethyl Ester 96% TC, and several formulations of Chlorpyriphos, Thiamethoxam, Pretilachlor, Metribuzin, Hexaconazole, and Metalaxyl. These products are manufactured for their clients, including corporations such as Aromatic Rasayan Private Limited, JR Jindal Infraprojects Private Limited, and SC Formulator Co. Ltd.;
Managing director
Mr. Arpit Gupta
Parent organisation
Ambey Laboratories Ltd
Strengths & Financials of Ambey Laboratories
The company's manufacturing facility in Behror, Rajasthan, holds ISO 9001:2015 and ISO 14001:2015 certifications for quality, environmental, and safety practices.
Ambey Laboratories has implemented backward integration in its production processes, achieving Zero Liquid Discharge (ZLD) status. This approach minimises emissions and waste generation, showcasing the company’s commitment to sustainable practices.
The company’s total income from operations has risen consistently from Rs 81.74 crore in FY21 to Rs 84.60 crore in FY22 to Rs 104.82 crore in FY23.
Ambey Laboratories handles and manufactures materials and products that are hazardous, corrosive, and flammable. These require specialised handling and storage to mitigate risks. Any incidents involving these materials could lead to significant disruptions, impacting the company's financial performance and operational stability.
Ambey Laboratories' revenue relies heavily on its top five customers, who accounted for 90.05% of the revenue for the period ending October 31, 2023, and 95.57% in FY23. The potential loss of these major customers, or a reduction in their orders, could significantly impact the company's revenue and profitability.
The company relies heavily on the smooth operation of its manufacturing facility in Sotanala, Rajasthan. Any disruption in its operations could adversely affect the company’s financial condition.
The company’s manufacturing operations are concentrated in a single geographical location. Any disruption in the business environment in this location can hurt the company’s prospects.
Ambey Laboratories has contingent liabilities totalling Rs 6.61 crore. If these liabilities materialise, it could negatively impact the company's financial standing.
The company has accrued significant debt, amounting to Rs 15.51 crore as of October 31, 2023. Any inability to service or repay this debt could affect the company’s operations.
Ambey Laboratories has also taken on unsecured loans totalling Rs 0.99 crore, repayable on demand. A call for repayment could strain the company's cash flows, affecting its ability to maintain smooth operations.
Ambey Laboratories Financials
*All values are in Rs. Cr
Application Details of Ambey Laboratories IPO
Apply as | Price band | Apply Range |
---|
Regular | ₹65 - 68 | ₹2 - 5 Lakh |
High Networth Individual | ₹65 - 68 | ₹2 - 5 Lakh |
For Ambey Laboratories IPO, eligible investors can apply as Regular.